Telomir Pharmaceuticals (TELO) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Telomir Pharmaceuticals reported total assets of $7.34M and total liabilities of $1.43M. Shareholders' equity was $5.91M, up 819.6% from $643.04K a year earlier. Total debt stood at $473.75K against $7.29M in cash and short-term investments, a net cash position of $6.81M. That puts debt-to-equity at 0.08, compared with 0.15 a year earlier.

Telomir Pharmaceuticals Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Telomir Pharmaceuticals, Inc. (TELO) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Current Assets
Cash and Cash Equivalents	7.29	1.27	0.00	0.00	0.00
Cash & Short-Term Investments	7.29	1.27	0.00	0.00	0.00
Accounts Receivable	0.00	0.00	0.13	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.05	0.06	0.30	0.00	0.00
Total Current Assets	7.34	1.32	0.44	0.00	0.00
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.00	0.00	0.00
Long-Term Investments	0.00	0.00	0.00	0.00	0.06
Other Non-Current Assets	0.00	0.00	4.34	0.05	0.00
Total Non-Current Assets	0.00	0.00	4.34	0.05	0.06
Total Assets	7.34	1.32	4.77	0.05	0.06
Current Liabilities
Accounts Payable	0.54	0.59	0.71	0.40	0.02
Short-Term Debt	0.47	0.09	0.10	0.00	0.12
Accrued Liabilities	0.42	-	-	-	-
Other Current Liabilities	0.47	0.00	0.53	0.58	0.12
Total Current Liabilities	1.43	0.68	1.34	0.99	0.14
Non-Current Liabilities
Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Total Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.43	0.68	1.34	0.99	0.14
Stockholders' Equity
Retained Earnings	-41.01	-30.60	-14.06	-0.99	-0.14
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00	-0.06
Additional Paid-in Capital	46.92	31.24	17.50	0.06	0.06
Shares Outstanding	34.38	29.76	29.61	29.61	-
Total Stockholders' Equity	5.91	0.64	3.44	-0.94	-0.14
Total Liabilities & Equity	7.34	1.32	4.77	0.05	0.06

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Telomir Pharmaceuticals Balance Sheet

How much debt does Telomir Pharmaceuticals have?

Telomir Pharmaceuticals had total debt of $473.75K as of Dec 31, 2025, against $7.29M in cash and short-term investments. Its debt-to-equity ratio was 0.08. Total debt was $93.43K a year earlier.

What are Telomir Pharmaceuticals's total assets?

Telomir Pharmaceuticals reported total assets of $7.34M as of Dec 31, 2025, up 454.5% from $1.32M a year earlier. Total liabilities were $1.43M.

What is Telomir Pharmaceuticals's shareholders' equity?

Telomir Pharmaceuticals's shareholders' equity was $5.91M as of Dec 31, 2025, or about $0.17 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition